J Korean Child Neurol Soc Search


Journal of the Korean Child Neurology Society 2003;11(1):73-81.
Published online May 30, 2003.
Weight Change associated with Oxcarbazepine Monotherapy of Childhood Epilepsy.
Young Mi Kim, Sang Ook Nam
Department of Pediatrics, College of Medicine, Pusan National University, Busan, Korea. weareone@pusan.ac.kr
To evaluate the changes of bodyweight associated with oxcarbazepine monotherapy in children with epilepsy. METHODS: We conducted a retrospective review of 71 childhood epileptic patients(40 boys, and 31 girls) attending Pusan National University Hospital on oxcarbazepine monotherapy for at least 3 months. We evaluated the changes of standard deviation scores (SDS) between the baseline bodyweight and the post-treatment bodyweight. RESULTS: The mean age of the patients at diagnosis was 7.3 years old and the mean bodyweight SDS at diagnosis was 0.389+/-1.560. After the administration of oxcarbazepine, the mean bodyweight SDS increased substantially to 0.577+/-1.795(P<0.05). Significant increase of the bodyweight SDS were observed especially in boys, children under 7 years old, patients with partial seizures, patients with idiopathic epilepspes, and patients with negative bodyweight SDS at diagnosis. CONCLUSION: Oxcarbazepine monotherapy was associated with significant weight gain in children with epilepsy. It is necessary to warn patients starting oxcarbazepine medication of the possible bodyweight gain and to advise to start diet and an routine exercise.
Key Words: Oxcarbazepine, Bodyweight standard deviation score


Browse all articles >

Editorial Office
50-1, Yonsei-ro, Seodaemun-gu, Seoul 03722, Korea
Tel: +82-2-2019-3350    Fax: +82-2-2019-4881    E-mail: editor@annchildneurol.org                

Copyright © 2022 by Korean Child Neurology Society.

Developed in M2PI

Close layer
prev next